Pharmafile Logo

News and Press Releases

Eisai Named on TIME100 Most Influential Companies 2024 List

3 June 2024 -- Tokyo, Japan -- Eisai Co announced today that TIME has selected Eisai as one of the TIME100 Most Influential Companies of 2024. TIME reveals the TIME100...

Category: Biotechnology, Other
Posted: June 3, 2024

Eisai
4-6-10 Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan

Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients

Safety of ALX-001 reinforced by new data presented at AD/PD 2024 Conference in Lisbon, Portugal Two oral doses selected for further study in Alzheimer’s and Parkinson’s disease patients. 11 March 2024...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 11, 2024

Allyx Therapeutics
info@allyxthera.com
555 Long Wharf Drive Floor 11 New Haven, CT 06511, US

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos Technology Significantly Increases Drug Delivery into Cells

Semaglutide is the active ingredient of weight loss medications Ozempic and Wegovy Semaglutide as an oleogel formulation using the BrainDos technology is internalised much more strongly than in an aqueous...

Category: Drug Delivery, Pharmaceutical
Posted: May 8, 2024

MetP Pharma
info@mattern-pharma.com
Schynweg 7 Office: St. Anna-Weg 16 P.O.Box 138 6376 Emmetten / Switzerland

New Data Demonstrate Sunbird Bio’s APEX Diagnostic Test Accurately Differentiates Key Alzheimer’s Disease Biomarker in Blood

Blood-based diagnostic effectively discriminated between patients who were positive versus negative for amyloid beta on PET scans Data will be shared in a poster presentation at AD/PD 2024 on 8-9...

Category: Biotechnology
Posted: March 5, 2024

Sunbird Bio
35 Cambridgepark Drive Suite 100 Cambridge, MA 02140

PharmaKure announces epigenetics collaboration with Sheffield Hallam University to understand mechanisms of Alzheimer’s Diseases

New collaboration will enhance ability to identify those more at risk of developing brain diseases to enable earlier interventions 29 February 2024 -- Manchester, UK -- PharmaKure, a clinical stage...

Category: Other
Posted: February 29, 2024

PharmaKure
info@pharmakure.com
Alderley Park Congleton Road Nether Alderley Open Access Lab 19S6 Macclesfield SK10 4TG

Galimedix Therapeutics announces new pre-clinical data with GAL-201 in an Alzheimer’s disease transgenic model to be presented at AD/PD 2024 Conference

Galimedix’s novel, orally administered small molecule offers the hope of changing the course of disease by targeting amyloid beta oligomers and protofibrils 28 February 2024 -- Maryland, US -- Galimedix...

Category: Biotechnology
Posted: February 28, 2024

Galimedix Therapeutics
info@galimedix.com
3704 Calvend Lane Kensington, MD 20895 USA

SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care

The three companies will collaborate to improve global access to advanced cancer testing and data, broadening access to cutting-edge science 18 October 2023 -- Boston, US and Rolle, Switzerland --...

Category: Biotechnology
Posted: October 19, 2023

SOPHiA Genetics
La Pièce 12, CH-1180 Rolle, Switzerland

PharmaKure announces study success for novel blood test to identify biomarkers in patients with Alzheimer’s Disease

Study confirms ALZmetrix whole blood test can detect people at high risk of developing full Alzheimer’s Disease 17 October 2023 -- Manchester, UK -- PharmaKure, a pharmaceutical company spun out...

Category: Clinical Trials, Drug Discovery
Posted: October 17, 2023

PharmaKure
info@pharmakure.com
Alderley Park Congleton Road Nether Alderley Open Access Lab 19S6 Macclesfield SK10 4TG